Login to Your Account



Arena's Obesity Drug Positive In First-Look Phase II Results

By Randall Osborne


Thursday, May 12, 2005
Favorable top-line data with its 28-day, Phase II trial of APD356, an oral drug for obesity, boosted Arena Pharmaceuticals Inc.'s stock, and the company has plans in the works for a longer study. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription